Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.

Completed

• Conditions: Breast Cancer; Pancreatic Cancer; Colorectal Cancer; Lung Cancer; Melanoma (Skin)

• Registration Number: NCT00974610
• Lead Sponsor: Cancer Trials Ireland

Brief Summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in peptides and proteins and identify biomarkers related to cancer.

PURPOSE: This research study is looking at blood samples from patients with malignant melanoma, metastatic breast cancer, advanced lung cancer, pancreatic cancer, or colorectal cancer.

Detailed Description

OBJECTIVES:

Primary

* To assess which potential peptide and protein markers produced by human melanoma, lung, breast, pancreatic, and colorectal cell lines may be detectable in serum of patients from these five disease groups.

Secondary

* To conduct further extensive investigation with respect to identification of the protein/peptide involved, determination of specificity for each cancer, and development of more sensitive assays to look for such markers in a wider population of patients, including those undergoing therapy.

OUTLINE: This is a multicenter study.

Blood samples are collected before surgical intervention or treatment to assess peptide and protein markers.

Study Timeline

• Study Start: 2008-08
• Study First Submitted: 2009-09-09
• Study First Submitted QC: 2009-09-09
• Study First Posted: 2009-09-10
• Primary Completion: 2015-12
• Study Completion: 2017-01
• Status Verified: 2017-05
• Last Update Submitted: 2017-05-23
• Last Update Posted: 2017-05-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 803

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Detection of peptide and protein markers in serum	Ongoing

Secondary Outcome Measures

Name	Time	Method
Identification of the protein/peptide involved	Ongoing

Trial Locations

Locations (13)

Mater Private Hospital; 🇮🇪 Dublin, Ireland

Mid-Western Cancer Centre at Mid-Western Regional Hospital; 🇮🇪 Limerick, Ireland

Cork University Hospital; 🇮🇪 Cork, Ireland

Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital; 🇮🇪 Dublin, Ireland

Beaumont Hospital; 🇮🇪 Dublin, Ireland

St. Vincent's University Hospital; 🇮🇪 Dublin, Ireland

Waterford Regional Hospital; 🇮🇪 Waterford, Ireland

University College Hospital; 🇮🇪 Galway, Ireland

Mercy University Hospital; 🇮🇪 Cork, Ireland

Mater Misericordiae University Hospital; 🇮🇪 Dublin, Ireland

St. James's Hospital; 🇮🇪 Dublin, Ireland

St Luke's Hospital; 🇮🇪 Dublin, Ireland

Letterkenny General Hospital; 🇮🇪 Letterkenny, Ireland